专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

JP2004285037A Trapping of growth factor midkine by lrp partial peptide 审中-公开
公开(公告)号：JP2004285037A
公开(公告)日：2004-10-14
申请号：JP2003124558
申请日：2003-03-24
申请人： Kenji Kadomatsu , Takashi Muramatsu , 喬村松 , 健治門松
发明人： KADOMATSU KENJI , GUOJUN BU , MURAMATSU TAKASHI
IPC分类号： C12N15/09 , C07K14/705
摘要： PROBLEM TO BE SOLVED: To provide a method for trapping midkine to specifically and intensely suppress the secretion of MK protein or specifically bond to secreted MK to inhibit the bonding of MK to a receptor.
SOLUTION: A region having high affinity especially to MK is found in the amino acid sequence of LRP (LDL receptor-related protein) which is an MK receptor and the peptide is excreted from a cell or expressed in an endoplasmic reticula by applying a reticula retention signal.
COPYRIGHT: (C)2005,JPO&NCIPI

2. 发明授权

US07820160B2 Midkine inhibitory compositions for the treatment of angiostenosis 有权
标题翻译：用于治疗血管狭窄的中期抑制组合物
公开(公告)号：US07820160B2
公开(公告)日：2010-10-26
申请号：US11936438
申请日：2007-11-07
申请人： Kenji Kadomatsu , Mitsuru Horiba , Takashi Muramatsu , Shinya Ikematsu , Sadatoshi Sakuma
发明人： Kenji Kadomatsu , Mitsuru Horiba , Takashi Muramatsu , Shinya Ikematsu , Sadatoshi Sakuma
IPC分类号： A61K39/395 , A61K48/00
CPC分类号： C12N15/1136 , A61K2039/505 , C07K14/475 , C07K16/22 , C12N15/1137 , C12N15/1138
摘要： The present invention provides a pharmaceutical composition for the prevention or treatment of angiostenosis, comprising a compound inhibiting the function of midkine (MK) in blood vessel tissues as an effective ingredient. The present invention is useful for the prevention or treatment of angiostenosis attributed to arteriosclerosis or restenosis after percutaneous transluminal coronary angioplasty (PTCA). As compounds inhibiting the function of MK, antisense oligonucleotides that bind to a segment of a single-stranded mRNA transcribed from the MK gene to inhibit the synthesis of MK protein in cells, antibodies against the MK protein, and such can be used.
摘要翻译：本发明提供了一种用于预防或治疗血管狭窄症的药物组合物，其包含抑制血管组织中的中期因子（MK）作为有效成分的功能的化合物。本发明可用于预防或治疗经皮腔内冠状动脉血管成形术（PTCA）后动脉硬化或再狭窄引起的血管狭窄。作为抑制MK功能的化合物，可以使用结合从MK基因转录的单链mRNA片段抑制细胞中MK蛋白合成的抗体的反义寡核苷酸等。

3. 发明申请

US20050079151A1 Therapeutic agents for apoptosis-related diseases 审中-公开
标题翻译：凋亡相关疾病的治疗剂
公开(公告)号：US20050079151A1
公开(公告)日：2005-04-14
申请号：US10641728
申请日：2003-08-15
申请人： Shinya Ikematsu , Yoshihiro Yoshida , Kenji Kadomatsu , Munehiro Oda , Sadatoshi Sakuma , Kin-ya Ashida , Kohsuke Kino , Takashi Muramatsu
发明人： Shinya Ikematsu , Yoshihiro Yoshida , Kenji Kadomatsu , Munehiro Oda , Sadatoshi Sakuma , Kin-ya Ashida , Kohsuke Kino , Takashi Muramatsu
IPC分类号： A61K38/18 , A61K38/19
CPC分类号： A61K38/18
摘要： Proteins belonging to the MK family can suppress apoptosis induced by various stimuli such as carcinostatics, ultraviolet light and radiation, ischemic stresses, etc. Based on this finding, the invention provides novel agents for treating or preventing various diseases attributed to apoptosis such as cerebropathy, cardiopathy, nephropathy, neuropathy, or hepatopathy, etc., comprising proteins belonging to the MK family as an effective ingredient.
摘要翻译：属于MK家族的蛋白质可以抑制由诸如制癌学，紫外光和辐射，缺血应激等各种刺激物诱导的凋亡。基于这一发现，本发明提供了用于治疗或预防由细胞凋亡引起的各种疾病如脑病，心脏病，肾病，神经病或肝病等，其包含属于MK家族的蛋白质作为有效成分。

4. 发明申请

US20110125075A1 METHOD FOR CONTROL OF ELECTROPORATION APPARATUS 审中-公开
标题翻译：电气设备控制方法
公开(公告)号：US20110125075A1
公开(公告)日：2011-05-26
申请号：US11988832
申请日：2006-07-14
申请人： Yoshifumi Takei , Kenji Kadomatsu , Tatsuya Fujishima , Takashi Muramatsu
发明人： Yoshifumi Takei , Kenji Kadomatsu , Tatsuya Fujishima , Takashi Muramatsu
IPC分类号： A61N1/30 , A01K67/027 , C12Q1/02
CPC分类号： A61N1/327 , A61K31/7088 , A61K38/1866 , A61K48/00 , A61N1/0424 , C12N15/111 , C12N15/1136 , C12N2310/14 , C12N2320/32 , C12N2320/51 , G01N33/5088
摘要： A method for controlling an electroporation apparatus for use in an animal such as human and a non-human animal, the method comprising a step of applying a voltage to an electrode of the electroporation apparatus placed in/on a biological sample of the animal in the presence of a nucleic acid construct capable of inhibiting the expression of a gene in the animal. In this manner, a nucleic acid construct can be introduced into a cell of a living body with good efficiency.
摘要翻译：一种用于控制动物如人和非人动物的电穿孔装置的方法，所述方法包括向放置在动物生物样品中的电穿孔装置的电极施加电压的步骤能够抑制动物中基因表达的核酸构建体的存在。以这种方式，可以以高效率将核酸构建体引入生物体的细胞。

5. 发明申请

US20110059102A1 Therapeutic Method Targeting Midkine 审中-公开
标题翻译：靶向中期药物的治疗方法
公开(公告)号：US20110059102A1
公开(公告)日：2011-03-10
申请号：US12554560
申请日：2009-09-04
申请人： Kenji KADOMATSU , Seiichi MATSUO , Yukio YUZAWA
发明人： Kenji KADOMATSU , Seiichi MATSUO , Yukio YUZAWA
IPC分类号： A61K39/395 , A61K31/7088 , A61P9/12 , A61P13/12
CPC分类号： A61K31/7088
摘要： Provided is a therapeutic method targeting midkine for treating mammalian kidney disorders, primary kidney disorders, hypertension that follows secondary kidney disorders such as diabetic nephropathy, and hypertension secondary to chronic kidney disease.
摘要翻译：本发明提供了一种靶向midkine治疗哺乳动物肾脏疾病，原发性肾脏疾病，继发性肾脏疾病如糖尿病肾病的高血压和继发于慢性肾脏疾病的高血压的治疗方法。

6. 发明授权

US07309695B2 Pharmaceutical compositions for the prevention and treatment of atherosclerosis and restenosis after PTCA 有权
标题翻译：用于预防和治疗PTCA后的动脉粥样硬化和再狭窄的药物组合物
公开(公告)号：US07309695B2
公开(公告)日：2007-12-18
申请号：US10703783
申请日：2003-11-06
申请人： Kenji Kadomatsu , Mitsuru Horiba , Takashi Muramatsu , Shinya Ikematsu , Sadatoshi Sakuma
发明人： Kenji Kadomatsu , Mitsuru Horiba , Takashi Muramatsu , Shinya Ikematsu , Sadatoshi Sakuma
IPC分类号： C07H21/04 , A61K48/00
CPC分类号： C12N15/1136 , A61K2039/505 , C07K14/475 , C07K16/22 , C12N15/1137 , C12N15/1138
摘要： The present invention provides a pharmaceutical composition for the prevention or treatment of angiostenosis, comprising a compound inhibiting the function of midkine (MK) in blood vessel tissues as an effective ingredient. The present invention is useful for the prevention or treatment of angiostenosis attributed to arteriosclerosis or restenosis after percutaneous transluminal coronary angioplasty (PTCA). As compounds inhibiting the function of MK, antisense oligonucleotides that bind to a segment of a single-stranded mRNA transcribed from the MK gene to inhibit the synthesis of MK protein in cells, antibodies against the MK protein, and such can be used.
摘要翻译：本发明提供了一种用于预防或治疗血管狭窄症的药物组合物，其包含抑制血管组织中的中期因子（MK）作为有效成分的功能的化合物。本发明可用于预防或治疗经皮腔内冠状动脉血管成形术（PTCA）后动脉硬化或再狭窄引起的血管狭窄。作为抑制MK功能的化合物，可以使用结合从MK基因转录的单链mRNA片段抑制细胞中MK蛋白合成的抗体的反义寡核苷酸等。

7. 发明授权

US6037159A Polypeptide of N-acetylglucosamine-6-O-sulfotransferase and DNA encoding the same 有权
标题翻译： N-乙酰葡糖胺-6-O-磺基转移酶的多肽和编码它们的DNA
公开(公告)号：US6037159A
公开(公告)日：2000-03-14
申请号：US263023
申请日：1999-03-05
申请人： Kenji Uchimura , Hideki Muramatsu , Kenji Kadomatsu , Reiji Kannagi , Osami Habuchi , Takashi Muramatsu
发明人： Kenji Uchimura , Hideki Muramatsu , Kenji Kadomatsu , Reiji Kannagi , Osami Habuchi , Takashi Muramatsu
IPC分类号： C12N15/09 , C07K16/28 , C07K16/44 , C12N9/10 , C12N15/54 , C12P19/04 , C12P19/26 , C12R1/91
CPC分类号： C07K16/2896 , C07K16/44 , C12N9/13 , C12P19/04
摘要： Apolypeptide of N-acetylglucosamine-6-O-sulfotransferase and a DNA encoding the peptide are provided. The polypeptide is (a) or (b) below:(a) a polypeptide consisting of an amino acid sequence represented by SEQ ID NO: 2; or(b) a polypeptide which comprises an amino acid sequence including substitution, deletion, insertion or transposition of one or few amino acids in the amino acid sequence of (a) and which has an enzymatic activity to transfer a sulfate group from a sulfate group donor to a hydroxyl group at 6 position of an N-acetylglucosamine residue located at a non-reducing end of an oligosaccharide represented by the formula I:GlcNAc.beta.1-3Gal.beta.1-4GlcNAc (I) wherein GlcNAc represents an N-acetylglucosamine residue, Gal represents a galactose residue, .beta.1-3 represents a .beta.1-3 glycosidic linkage, and .beta.1-4 represents a .beta.1-4 glycosidic linkage.
摘要翻译：提供N-乙酰氨基葡萄糖-6-O-磺基转移酶的多肽和编码该肽的DNA。多肽为（a）或（b）：（a）由SEQ ID NO：2所示的氨基酸序列组成的多肽; 或（b）包含在（a）的氨基酸序列中包含一个或几个氨基酸的取代，缺失，插入或转座的氨基酸序列的多肽，其具有从硫酸基团转移硫酸基团的酶活性供体位于位于由式I表示的寡糖的非还原性末端的N-乙酰葡糖胺残基的6位的羟基：GlcNAcβ1〜3Galβ1-4GlcNAc（I），其中GlcNAc表示N-乙酰氨基葡萄糖残基 Gal代表半乳糖残基，β1-3代表β1-3糖苷键，β1-4代表β1-4糖苷键。

8. 发明申请

US20110275137A1 IMPROVING AGENT FOR NEUROPATHIC PAIN 审中-公开
标题翻译：改善神经痛疼痛剂
公开(公告)号：US20110275137A1
公开(公告)日：2011-11-10
申请号：US12937456
申请日：2009-04-14
申请人： Yukihiro Matsuyama , Kenji Kadomatsu , Shiro Imagama , Akiomi Tanaka
发明人： Yukihiro Matsuyama , Kenji Kadomatsu , Shiro Imagama , Akiomi Tanaka
IPC分类号： C12N9/88
CPC分类号： A61K38/51 , C07D471/10 , C12N9/2402 , C12Y302/01096
摘要： An object of the present invention is to provide a substance which can be used as an active ingredient for improving neuropathic pain having a novel mechanism of action different from those of currently available agents and, therefore, provide an improving agent for neuropathic pain which rarely interacts with currently available agents and also does not have adverse reactions similar to those of currently available agents. An improving agent for neuropathic pain due to a hyperalgesic response of the present invention as a means for resolution is characterized by comprising, as an active ingredient, a lyase (an elimination enzyme) which has an activity of degrading a chondroitin sulfate chain of a chondroitin sulfate proteoglycan, and is typified by chondroitinase ABC which selectively removes chondroitin sulfate and dermatan sulfate of a proteoglycan.
摘要翻译：本发明的目的是提供一种物质，其可用作改善神经性疼痛的活性成分，其具有与目前可获得的药剂不同的新作用机制，因此提供了很少相互作用的神经性疼痛的改善剂使用目前可获得的药剂，也没有类似于当前可用药剂的不良反应。作为解决手段的由于本发明的镇痛反应引起的神经性疼痛的改善剂的特征在于，作为活性成分，含有降解软骨素硫酸软骨素链的活性的裂解酶（消除酶）硫酸蛋白聚糖，并且以软骨素酶ABC为代表，其选择性地去除蛋白多糖的硫酸软骨素和硫酸皮肤素。

9. 发明申请

US20110111427A1 BIOMARKER FOR THE ESTIMATION OF ACUTE RENAL DISORDER AND PROGNOSIS OF THE DISORDER, AND USE OF THE BIOMARKER 审中-公开
标题翻译：生物标志物用于估计急性肾功能衰竭和预防疾病，以及生物标志物的使用
公开(公告)号：US20110111427A1
公开(公告)日：2011-05-12
申请号：US12919887
申请日：2009-02-26
申请人： Kenji Kadomatsu , Yukio Yuzawa , Hiroki Hayashi , Seiichi Matsuo , Shinya Ikematsu
发明人： Kenji Kadomatsu , Yukio Yuzawa , Hiroki Hayashi , Seiichi Matsuo , Shinya Ikematsu
IPC分类号： G01N33/573 , G01N33/53 , C07K16/24
CPC分类号： G01N33/74 , G01N2333/515 , G01N2800/347 , G01N2800/56
摘要： To provide a novel biomarker that is useful for prediction of early onset of acute kidney injury, estimation of prognosis associated with a renal function, and differentiation of acute kidney injury. Furthermore, to provide use of the novel biomarker. Midkine is used as a biomarker. The determination of a possibility of the onset of acute kidney injury, estimation of prognosis associated with a renal function or differentiation of an acute kidney injury are carried out based on the detection result of the urinary midkine.
摘要翻译：提供可用于预测急性肾损伤早期发作，估计与肾功能相关的预后以及急性肾损伤分化的新型生物标志物。此外，为了提供新型生物标志物的使用。 Midkine被用作生物标志物。基于尿中期因子的检测结果，确定急性肾损伤发作的可能性，与肾功能相关的预后的估计或急性肾损伤的分化。

10. 发明申请

US20100197577A1 NITRIC OXIDE SYNTHASE ACTIVATOR 有权
标题翻译：硝酸氧化酶活化剂
公开(公告)号：US20100197577A1
公开(公告)日：2010-08-05
申请号：US12593277
申请日：2008-03-28
申请人： Mitsuru Horiba , Kenji Kadomatsu , Itsuo Kodama , Takashi Muramatsu , Hisaaki Ishiguro , Hiroharu Takenaka , Arihiro Sumida
发明人： Mitsuru Horiba , Kenji Kadomatsu , Itsuo Kodama , Takashi Muramatsu , Hisaaki Ishiguro , Hiroharu Takenaka , Arihiro Sumida
IPC分类号： A61K38/16 , C12N9/00
CPC分类号： C07K14/475 , A61K38/00
摘要： The object is to find a nitric oxide synthase activator, a method for the administration of the activator, and the amount of the activator to be administered. Disclosed is a nitric oxide synthase activator comprising a midkine family protein or a midkine derivative as an active ingredient. Specifically disclosed is a nitric oxide synthase activator which is intended to be administered through the blood, a coronary artery or a vein and which comprises a midkine family protein or a midkine derivative as an active ingredient.
摘要翻译：目的是找到一氧化氮合酶激活剂，给予激活剂的方法和待施用的活化剂的量。公开了包含中期因子家族蛋白或中期因子衍生物作为活性成分的一氧化氮合酶激活剂。具体公开了旨在通过血液，冠状动脉或静脉施用的一氧化氮合酶激活剂，其包含中期因子家族蛋白或中期因子衍生物作为活性成分。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式